Explore 3 Stock Ideas & Industry Insights Download Free Report

Healthcare

Achieve Life Sciences (NASDAQ:ACHV) Rises 8% as Smoking-Cessation Biotech Draws Fresh Interest

• Achieve Life Sciences (ACHV) was identified as one of the top gaining US stocks, rising around 8% in a single trading session.

Vinay Lochav | 26 June 2026

Aktis Oncology (NASDAQ:AKTS) Gains 9%: Cancer-Therapy Stock Finds Fresh Momentum

• Aktis Oncology (AKTS) was identified as one of the top gaining US stocks, rising around 9% in a single trading session.

Vinay Lochav | 26 June 2026

Alamar Biosciences (NASDAQ:ALMR) Gains 13%: Life-Sciences Stock Finds Fresh Momentum

• Alamar Biosciences (ALMR) was identified as one of the top gaining US stocks, rising around 13% in a single trading session.

Vinay Lochav | 26 June 2026

Alpha Tau Medical (NASDAQ:DRTS) Rises 11% as Cancer-Treatment Stocks Return to Focus

• Alpha Tau Medical (DRTS) was identified as one of the top gaining US stocks, rising around 11% in a single trading session.

Vinay Lochav | 26 June 2026

Apollomics (NASDAQ:APLM) Jumps 7% as Cancer Biotech Speculation Heats Up

• Apollomics (APLM) was identified as one of the top gaining US stocks, rising around 7% in a single trading session.

Vinay Lochav | 26 June 2026

Ascendis Pharma (NASDAQ:ASND) Rallies 10% as Biotech Strength Returns to Large-Cap Names

• Ascendis Pharma (ASND) was identified as one of the top gaining US stocks, rising around 10% in a single trading session.

Vinay Lochav | 26 June 2026

AbCellera (NASDAQ:ABCL) Jumps 10% as AI-Driven Biotech Screening Gains Investor Interest

• AbCellera (ABCL) was identified as one of the top gaining US stocks, rising about 10% in a single trading session.

Vinay Lochav | 26 June 2026

Acadia Pharmaceuticals (NASDAQ: ACAD) Receives CHMP Positive Re-Examination Opinion for Daybue in Rett Syndrome — EU's First Potential Approved Therapy for the Rare Neurodevelopmental Disorder

The EMA's Committee for Medicinal Products for Human Use issued a positive re-examination opinion recommending EU approval of Daybue (trofinetide) for neurobehavioral symptoms of Rett syndrome in patients aged five and older — positioning it to become the first pharmacological therapy approved for this …

Vinay Lochav | 26 June 2026

ProQR Therapeutics (NASDAQ: PRQR) Prices $50 Million Registered Direct Offering With Eli Lilly Participating in Concurrent $9.2 Million Private Placement to Advance Axiomer RNA-Editing Platform

ProQR Therapeutics priced a registered direct offering of common shares at $1.81 per share targeting $50 million in gross proceeds, with Eli Lilly and Company committing $9.2 million via a concurrent private placement to preserve its pro rata ownership stake in the company.

Vinay Lochav | 26 June 2026

Shuttle Pharmaceutical Holdings (NASDAQ: SHPH) Pivots Toward Owned Digital Infrastructure as United Dogecoin Evaluates Data Center and Behind-the-Meter Power Assets in Idaho and Alberta

Shuttle Pharmaceutical Holdings' recently acquired subsidiary United Dogecoin is evaluating proprietary data center and behind-the-meter power assets in Idaho and Alberta while electrifying initial ElphaPex miners, positioning the company to shift from basic Dogecoin mining toward owned digital infrastructure with potential artificial intelligence hosting …

Vinay Lochav | 26 June 2026
Support

Hi! How can we help you today?

Loading…